{"id":"phase-1-perphenazine","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Extrapyramidal symptoms (tremor, rigidity, akathisia)"},{"rate":null,"effect":"Tardive dyskinesia"},{"rate":"10-20","effect":"Sedation"},{"rate":"5-15","effect":"Orthostatic hypotension"},{"rate":null,"effect":"Prolactin elevation"},{"rate":"5-10","effect":"Weight gain"}]},"_chembl":{"chemblId":"CHEMBL567","moleculeType":"Small molecule","molecularWeight":"403.98"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Perphenazine antagonizes dopamine D2 receptors in the mesolimbic and mesocortical pathways, which reduces hallucinations, delusions, and disorganized thinking characteristic of psychotic disorders. It also has some activity at other dopamine receptors and serotonin receptors, contributing to its antipsychotic and antiemetic effects.","oneSentence":"Perphenazine is a typical antipsychotic that blocks dopamine D2 receptors in the brain to reduce psychotic symptoms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:50:37.525Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Psychotic disorders"},{"name":"Severe nausea and vomiting"}]},"trialDetails":[{"nctId":"NCT03510325","phase":"PHASE3","title":"Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2019-02-12","conditions":"Schizophrenia","enrollment":762},{"nctId":"NCT01594749","phase":"PHASE3","title":"Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-09-24","conditions":"Chemotherapy-Induced Nausea and Vomiting (CINV)","enrollment":1015},{"nctId":"NCT01765829","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza Progreso y Salud","startDate":"2012-11","conditions":"Psychosis Nos/Other","enrollment":104},{"nctId":"NCT01363349","phase":"PHASE2, PHASE3","title":"Phase IIb-III Study of BL-1020 Small Molecule for Schizophrenia","status":"TERMINATED","sponsor":"BioLineRx, Ltd.","startDate":"2011-05","conditions":"Schizophrenia, Cognitive Effect on Schizophrenic Patients","enrollment":269},{"nctId":"NCT00567710","phase":"PHASE2","title":"A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study","status":"COMPLETED","sponsor":"BioLineRx, Ltd.","startDate":"2008-07","conditions":"Schizophrenia","enrollment":360}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":72,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Phase 1: Perphenazine","genericName":"Phase 1: Perphenazine","companyName":"Shanghai Mental Health Center","companyId":"shanghai-mental-health-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Perphenazine is a typical antipsychotic that blocks dopamine D2 receptors in the brain to reduce psychotic symptoms. Used for Schizophrenia, Psychotic disorders, Severe nausea and vomiting.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}